Osteoclast microRNA Profiling in Rheumatoid Arthritis to Capture the Erosive Factor.

Area of Science:

• Biochemistry
• Molecular Biology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) can lead to irreversible bone destruction in a subset of patients.
• Identifying biomarkers for erosive RA is crucial for timely intervention and personalized treatment.

Purpose of the Study:

• To discover a microRNA (miR)-based signature in osteoclasts that predicts bone erosiveness in rheumatoid arthritis (RA).
• To evaluate the predictive value of miRs and their target genes, combined with clinical data, for identifying erosive RA phenotypes.

Main Methods:

• Peripheral blood mononuclear cell (PBMC)-derived osteoclasts from RA patients (erosive and nonerosive) and healthy controls were analyzed for miR and target gene expression.
• Quantitative PCR (qPCR) and RNA-Seq were used for miR and gene expression profiling.
• Machine-learning models integrated miR expression, target gene data, and clinical factors (e.g., rheumatoid factor titer) to predict RA erosion.

Main Results:

• Five miRs were found to be differentially expressed in RA osteoclasts, with specific miRs altered in erosive versus nonerosive RA or controls.
• In vitro inhibition of hsa-miR-34a-3p affected osteoclast bone resorption.
• A predictive model combining miRs (primarily hsa-miR-365b-3p) and rheumatoid factor titer achieved 70% accuracy (AUC 0.66).
• Incorporating target genes significantly improved the model's predictive power for erosive RA to 78% accuracy (AUC 0.85).

Conclusions:

• MicroRNA expression profiling in PBMC-derived osteoclasts can help identify RA patients at risk of bone erosion.
• This miR-based signature, especially when combined with target gene analysis and clinical data, offers a promising approach for predicting RA erosiveness.
• The findings suggest novel avenues for personalized treatment strategies in RA management.